Pacific Biosciences Of Calif (PACB) 13F Filing Data & Analysis (Q2 2026)

PACB ranks #2732 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PACB is a disclosed holding of Cathie Wood (ARK Investment Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.3% of that fund's own 13F portfolio.

224 institutions disclose a position in PACB, but none treat it as a major bet — even Birchview Capital, LP, its most concentrated holder, allocates just 1.1% of its own portfolio to it.

Cliff Asness has added to its PACB position for two straight quarters, increasing it by $2.0M to reach $2.2M today.

Jim Simons has trimmed its PACB position for two straight quarters, cutting it by $5.6M while still holding $1.6M.

PACB is up 2.6% today, and institutions have been net buyers of $14.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PACB reported a net loss of $131.4M over the trailing twelve months.

• Not yet profitable — net loss of $131.4M over the trailing twelve months
• Revenue grew 1.0% year over year
• Net income improved year over year, from -$526.4M to -$131.4M
• Operating cash flow was negative, using $111.2M in cash
• Current ratio of 5.15x — enough short-term assets to cover short-term liabilities
• Liabilities run 145.59x equity — a highly leveraged balance sheet worth noting